Intimation of Q1 FY27- Earnings Presentation.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 19 Jul 2026, 04:18 PM IST · BSE ID: 0263cef7-7a4b-40d7-ae78-ef1b9667415c
View Original BSE Filing (PDF)
💡
In Simple Terms
Rossari Biotech released its first-quarter results for the financial year 2027, showing higher sales and profit compared to last year.
🤖 AI Summary
- Consolidated Revenue from Operations for Q1 FY27 was Rs. 697.2 cr, a 28.2% increase year-on-year.
- EBITDA for Q1 FY27 stood at Rs. 80.6 cr, marking an 18.7% year-on-year growth.
- Profit After Tax (PAT) for Q1 FY27 was Rs. 35.1 cr, a 4.5% increase compared to Q1 FY26.
- HPPC, TSC, and AHN businesses reported YoY revenue growth of 28%, 28%, and 27% respectively.
- Rossari Biotech established a greenfield blending facility in Thailand and sold its Andheri office.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenues from Operations (Consolidated) Q1 FY27
697.2 Rs. cr
28.2%
EBITDA (Consolidated) Q1 FY27
80.6 Rs. cr
18.7%
PAT (Consolidated) Q1 FY27
35.1 Rs. cr
4.5%
EBITDA Margin Q1 FY27
11.6%
(90) bps
PAT Margin Q1 FY27
5.0%
(120) bps
HPPC Revenue Growth (YoY) Q1 FY27
28%
TSC Revenue Growth (YoY) Q1 FY27
28%
AHN Revenue Growth (YoY) Q1 FY27
27%
🏢 How This Affects the Company
Consolidated revenue growth of 28.2% YoY, with all core segments (HPPC, TSC, AHN) growing by 27-28% YoY, indicates sustained demand and market penetration. The new Thailand facility expands the company's regional presence in Southeast Asia and enhances capabilities for customized formulations.
Revenue increased to Rs. 697.2 cr, and PAT rose to Rs. 35.1 cr, reflecting top-line growth. However, EBITDA margin decreased by 90 bps to 11.6% and PAT margin by 120 bps to 5.0% YoY, influenced by a 32.2% rise in COGS and 93.0% increase in finance costs.
The new blending facility in Thailand, with an installed capacity of 5,000 MTPA, supports localized production and supply-chain efficiency in Southeast Asia. Monetization of non-core assets, including the sale of the Andheri office, streamlines the company's asset base.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this earnings presentation.
👤
Who Is Affected
All shareholders are affected as the financial results provide an update on the company's performance, showing a 4.5% YoY increase in PAT to Rs. 35.1 cr.
🔍
Management Signal
Management is focused on expanding global presence, optimizing capacity utilization from past investments, and monetizing non-core assets to strengthen the balance sheet.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor EBITDA and PAT margin trends.
Updates on Thailand facility utilization and contribution to revenue.
Further progress on monetisation of non-core assets.
LOW RISK
No new significant risks identified; strong revenue growth noted.
💡 Investor Takeaway
Rossari Biotech reported Q1 FY27 consolidated revenue of Rs. 697.2 cr, an increase of 28.2% YoY, and PAT of Rs. 35.1 cr, up 4.5% YoY. EBITDA margin was 11.6%, a 90 bps YoY decrease. The company expanded its international presence with a new Thailand facility.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Revenue from Operations grew 28.2% YoY to Rs. 697.2 cr, demonstrating strong top-line performance.
- Core segments HPPC, TSC, and AHN all reported robust YoY revenue growth of 28%, 28%, and 27% respectively.
⚠️ Concerns
- EBITDA Margin declined by 90 bps YoY to 11.6% in Q1 FY27, down from 12.5% in Q1 FY26.
- Profit After Tax (PAT) Margin decreased by 120 bps YoY to 5.0% in Q1 FY27, from 6.2% in Q1 FY26.
📅 Company Track Record
Rossari Biotech has demonstrated a consistent growth trajectory, with a Revenue CAGR of 13%, EBITDA CAGR of 9%, and PAT CAGR of 12% from FY19-26. The company reported consolidated revenues of Rs. 2,396.4 cr for FY26 and PAT of Rs. 149.2 cr for FY26.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Rossari Biotech's consolidated revenue from operations in Q1 FY27?
Rossari Biotech's consolidated revenue from operations for Q1 FY27 was Rs. 697.2 cr, an increase of 28.2% compared to Q1 FY26.
What was the EBITDA reported by Rossari Biotech for Q1 FY27?
The consolidated EBITDA for Rossari Biotech in Q1 FY27 was Rs. 80.6 cr, representing an 18.7% increase year-on-year.
What was Rossari Biotech's Profit After Tax (PAT) in Q1 FY27?
Rossari Biotech reported a consolidated Profit After Tax (PAT) of Rs. 35.1 cr for Q1 FY27, a 4.5% rise from Q1 FY26.
How did Rossari Biotech's core business segments perform in Q1 FY27?
In Q1 FY27, the HPPC, TSC, and AHN businesses of Rossari Biotech delivered YoY revenue growth of 28%, 28%, and 27% respectively.
What new facility did Rossari Biotech establish in Q1 FY27?
Rossari Biotech established a greenfield blending facility in Thailand through its subsidiary, Unistar Thai, with an installed capacity of 5,000 MTPA in Q1 FY27.
Questions based on this BSE filing only. For information purposes.